Project Grant K01AI193303
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $690,538 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of Washington for the project "EXPANDING ACCESS AND IMPACT OF TUBERCULOSIS PREVENTIVE THERAPY: COMMUNITY-FRIENDLY DELIVERY AND MONITORING OF TPT TO IMPROVE UPTAKE AND REDUCE TB TRANSMISSION." The project aims to explore new, person-friendly models of tuberculosis preventive therapy (TPT) delivery to...
- This $1,173,748.00 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), will fund research on the role of asymptomatic tuberculosis (TB) in disease transmission. The research aims to improve understanding of when individuals become infectious and where transmission is occurring, particularly in community settings outside of household contacts. Key areas of focus include characterizing...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $253,497 Project Grant under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855) to The Trustees of Columbia University in the City of New York for the project "MOBILIZING INNOVATIVE STRATEGIES TO IMPROVE TB DIAGNOSIS AND RETENTION IN THE TB CARE CASCADE FOR MIGRANT COMMUNITIES IN NEW YORK CITY". The project aims to evaluate innovative methods, including a mobile diagnostic platform...
- This $193,375 Project Grant, awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to identify bacterial determinants that may contribute to variable treatment responses for tuberculosis (TB). The project, conducted by researchers at the Harvard T.H. Chan School of Public Health, aims to investigate the effects of clinically prevalent variants in the ESX1 secretion system on TB...
- This Project Grant award, valued at $2,324,448.00, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The purpose is to optimize an oral BCG (Bacille Calmette-Guerin) vaccination regimen against tuberculosis (TB), a leading cause of infectious death worldwide. The research aims to: 1) Optimize the oral BCG regimen, 2) Compare the efficacy of oral BCG to intravenous and intradermal BCG in...
- This $209,408 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research (CFDA 93.855) program, supports a research project to characterize the role of unconventional T cell subsets in the immune response to Mycobacterium tuberculosis (MTB) infection using a non-human primate model. The goal is to gain a better understanding of these niche T cell populations in the lung granulomas during the early stages of MTB...
- This $162,000 Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports research to characterize the role of plasmacytoid dendritic cells (PDCs) in Mycobacterium tuberculosis (MTB) infection. The research aims to quantify PDC trafficking and activation in the lungs during MTB infection, and determine how PDC-driven type I interferon responses impact MTB control. The project will leverage a mouse model that...
- This Project Grant award of $3,145,850.00 was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research (CFDA 93.855) federal grant program. The award supports research at The Johns Hopkins University to investigate macrophage senescence as a driver of granuloma failure and necrosis in pulmonary tuberculosis (TB) and TB/HIV coinfection. Key objectives include understanding the role of stress-induced senescence in myeloid...
- This $854,000 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), aims to assess post-tuberculosis (TB) lung disease in TB patients with and without HIV coinfection. The project will utilize novel positron emission tomography (PET) imaging techniques, such as 11C-rifampin PET, to longitudinally profile lesional characteristics and antibiotic exposures in animal models...
- This Project Grant award of $375,996.00 from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), supports research to assess the potential carriage state of Mycobacterium tuberculosis (MTB) in the upper respiratory tract of individuals who have been exposed to tuberculosis (TB) but do not display active disease. The research aims to understand the mechanisms by which the majority of people...
This $190,892 Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) will support a study to optimize tuberculosis (TB) active case finding strategies in Nairobi, Kenya. The key products and services to be delivered include: Employing multiple data sources on human mobility and activity spaces to identify high-yield geographic locations for TB screening within Nairobi. Developing a geospatial model to estimate neighborhood-level TB burden in Nairobi using prevalence survey data, case notifications, and other spatial factors. Producing an individual-based TB transmission model to simulate the impact of spatially-targeted active case finding strategies in Nairobi. The award will be administered by the University of Washington from August 1, 2025 to July 31, 2030. The goal is to leverage spatial approaches to optimize TB active case finding and thereby improve early diagnosis and treatment to prevent onward disease transmission.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $30.3k | 9/17/25 | ||
| Not listed | $160.6k | 9/9/25 |